{"id":"pertuzumab-injection","safety":{"commonSideEffects":[{"rate":"60–70","effect":"Diarrhea"},{"rate":"40–50","effect":"Nausea"},{"rate":"30–40","effect":"Fatigue"},{"rate":"20–30","effect":"Vomiting"},{"rate":"10–20","effect":"Rash"},{"rate":"5–10","effect":"Left ventricular dysfunction"},{"rate":"5–15","effect":"Febrile neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pertuzumab targets the extracellular domain II of HER2, a different epitope than trastuzumab, and prevents HER2 from forming heterodimers with HER3 and other HER family members. This dual blockade mechanism—combined with trastuzumab's direct HER2 inhibition—provides complementary anti-tumor activity. The drug is used in combination with trastuzumab and chemotherapy to enhance efficacy in HER2-positive cancers.","oneSentence":"Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:08.023Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)"},{"name":"HER2-positive early-stage breast cancer (neoadjuvant and adjuvant settings)"}]},"trialDetails":[{"nctId":"NCT07495930","phase":"PHASE1","title":"A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 and EU-Phesgo®.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-04-30","conditions":"Health Adult Subjects","enrollment":24},{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":"HER2-positive Breast Cancer","enrollment":544},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT07294508","phase":"PHASE2, PHASE3","title":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-02-27","conditions":"HER2 + Breast Cancer","enrollment":706},{"nctId":"NCT05132582","phase":"PHASE3","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-03-07","conditions":"HER2 Positive Breast Cancer","enrollment":654},{"nctId":"NCT07470203","phase":"","title":"Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03-31","conditions":"HER2-positive Breast Cancer","enrollment":42},{"nctId":"NCT04001829","phase":"PHASE2","title":"Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-08-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":249},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT06057610","phase":"PHASE3","title":"A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-10-16","conditions":"HER2-PositiveRecurrent or Metastatic Breast Cancer","enrollment":868},{"nctId":"NCT05593094","phase":"PHASE1, PHASE2","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-03","conditions":"Advanced Solid Tumors, HER2-positive Breast Cancer","enrollment":210},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT02947685","phase":"PHASE3","title":"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-06-21","conditions":"HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer","enrollment":518},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT07386938","phase":"PHASE3","title":"A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-09","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":246},{"nctId":"NCT07196774","phase":"PHASE3","title":"A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-10-23","conditions":"Early-stage or Locally Advanced HER2-positive Breast Cancer","enrollment":740},{"nctId":"NCT06828588","phase":"EARLY_PHASE1","title":"Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2026-02","conditions":"Locally Advanced Cancer, Metastatic Cancer, HER2","enrollment":30},{"nctId":"NCT05150691","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"DualityBio Inc.","startDate":"2022-01-31","conditions":"HER2-positive Advanced Solid Tumor","enrollment":796},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT03199885","phase":"PHASE3","title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-05","conditions":"Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma","enrollment":190},{"nctId":"NCT07299890","phase":"PHASE2","title":"An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-12-20","conditions":"Breast Cancer","enrollment":90},{"nctId":"NCT07294534","phase":"PHASE2, PHASE3","title":"A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-01-27","conditions":"HER2 + Breast Cancer","enrollment":817},{"nctId":"NCT07150767","phase":"PHASE1","title":"A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Beijing Bio-Targeting Therapeutics Technology Co., Ltd","startDate":"2025-03-26","conditions":"Locally Advanced Breast Cancer (LABC)","enrollment":""},{"nctId":"NCT05180006","phase":"PHASE2","title":"Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2022-02-24","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT07246317","phase":"PHASE2","title":"Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-15","conditions":"Breast Cancer","enrollment":188},{"nctId":"NCT05041842","phase":"PHASE2","title":"Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2021-12-17","conditions":"Metastatic Breast Cancer With a Isolated Brain Progression","enrollment":53},{"nctId":"NCT04329065","phase":"PHASE2","title":"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-04-20","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":25},{"nctId":"NCT06178159","phase":"PHASE2","title":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-11-28","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT07095023","phase":"NA","title":"Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-15","conditions":"Breast Cancers","enrollment":112},{"nctId":"NCT06414733","phase":"PHASE1","title":"HER-2 B Cell Peptide Vaccine","status":"RECRUITING","sponsor":"Pravin T.P Kaumaya","startDate":"2025-01-17","conditions":"Metastatic Breast Cancer, Metastatic Gastrointestinal Carcinoma, HER2-positive Breast Cancer","enrollment":42},{"nctId":"NCT02003209","phase":"PHASE3","title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-02-18","conditions":"HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7","enrollment":315},{"nctId":"NCT06172127","phase":"PHASE2","title":"PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-07-22","conditions":"HER2-positive Breast Cancer","enrollment":165},{"nctId":"NCT06441890","phase":"PHASE2","title":"BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2024-12-05","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":28},{"nctId":"NCT07057427","phase":"PHASE3","title":"Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-06-24","conditions":"Breast Cancer","enrollment":812},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":"Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic","enrollment":72},{"nctId":"NCT07003074","phase":"PHASE3","title":"A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-06-23","conditions":"Breast Cancer","enrollment":642},{"nctId":"NCT05346224","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-04-25","conditions":"Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer","enrollment":900},{"nctId":"NCT05319873","phase":"PHASE1, PHASE2","title":"Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2022-04-07","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":18},{"nctId":"NCT03161353","phase":"PHASE2","title":"Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2017-06-26","conditions":"Breast Cancer","enrollment":377},{"nctId":"NCT05332561","phase":"PHASE2","title":"Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)","status":"RECRUITING","sponsor":"German Cancer Research Center","startDate":"2023-06-29","conditions":"Early-stage Breast Cancer","enrollment":240},{"nctId":"NCT06276868","phase":"PHASE2","title":"Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-01-20","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":71},{"nctId":"NCT06718335","phase":"NA","title":"Pyrotinib in HER2-positive Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Nie Jianyun","startDate":"2024-12-30","conditions":"HER2-positive Breast Cancer","enrollment":156},{"nctId":"NCT04675827","phase":"PHASE2","title":"De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2022-01-17","conditions":"HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer","enrollment":139},{"nctId":"NCT05275010","phase":"PHASE1","title":"A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-05-30","conditions":"Healthy Male Subjects","enrollment":151},{"nctId":"NCT06510465","phase":"PHASE2","title":"Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-08-01","conditions":"Breast Cancer","enrollment":143},{"nctId":"NCT04629846","phase":"PHASE3","title":"Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2020-11-23","conditions":"Breast Cancer","enrollment":517},{"nctId":"NCT03272477","phase":"PHASE2","title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-10-05","conditions":"Breast Neoplasms","enrollment":257},{"nctId":"NCT05159193","phase":"PHASE3","title":"Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-20","conditions":"Breast Cancer","enrollment":372},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT04197687","phase":"PHASE2","title":"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery","status":"UNKNOWN","sponsor":"Academic and Community Cancer Research United","startDate":"2020-02-20","conditions":"Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7","enrollment":480},{"nctId":"NCT05353361","phase":"PHASE2","title":"A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-05-23","conditions":"Breast Cancer","enrollment":402},{"nctId":"NCT01376505","phase":"PHASE1","title":"Vaccine Therapy in Treating Patients With Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Robert Wesolowski","startDate":"2011-06-21","conditions":"Malignant Solid Tumour, Breast Cancer, Malignant Tumor of Colon","enrollment":65},{"nctId":"NCT05985187","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-10-20","conditions":"HER2-positive Breast Cancer","enrollment":412},{"nctId":"NCT05983094","phase":"PHASE2","title":"Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-09-01","conditions":"Breast Cancer, Neoadjuvant Therapy","enrollment":181},{"nctId":"NCT05945368","phase":"PHASE2","title":"A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-02-25","conditions":"HER2-positive Breast Cancer","enrollment":78},{"nctId":"NCT05323981","phase":"PHASE1","title":"Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection","status":"COMPLETED","sponsor":"BioRay Pharmaceutical Co., Ltd.","startDate":"2022-04-11","conditions":"Similarity of Pharmacokinetics and Safety","enrollment":180},{"nctId":"NCT05720026","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-01-09","conditions":"HER2-positive Breast Cancer","enrollment":560},{"nctId":"NCT05471648","phase":"PHASE1","title":"A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"EirGenix, Inc.","startDate":"2022-05-16","conditions":"Breast Cancer","enrollment":135},{"nctId":"NCT05656079","phase":"NA","title":"To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study","status":"UNKNOWN","sponsor":"Shanghai Pudong Hospital","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT04395508","phase":"","title":"An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic","status":"APPROVED_FOR_MARKETING","sponsor":"Genentech, Inc.","startDate":"","conditions":"HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT05420454","phase":"PHASE4","title":"A Study for the Neoadjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-10","conditions":"Breast Cancer","enrollment":1576},{"nctId":"NCT05420467","phase":"PHASE4","title":"A Study for the Adjuvant Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-10","conditions":"Breast Cancer","enrollment":2413},{"nctId":"NCT01847001","phase":"PHASE2","title":"Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-10","conditions":"Locally Advanced Malignant Neoplasm, Breast Cancer","enrollment":10},{"nctId":"NCT04820439","phase":"PHASE1","title":"Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2020-10-13","conditions":"Healthy Volunteers","enrollment":88},{"nctId":"NCT04337658","phase":"PHASE3","title":"Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-07-01","conditions":"HER2-positive Breast Cancer","enrollment":493},{"nctId":"NCT02689921","phase":"PHASE2","title":"NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer","status":"UNKNOWN","sponsor":"Midwestern Regional Medical Center","startDate":"2016-04","conditions":"Breast Neoplasms","enrollment":7},{"nctId":"NCT02738970","phase":"PHASE1","title":"A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-06-23","conditions":"Early Breast Cancer","enrollment":88},{"nctId":"NCT02125344","phase":"PHASE3","title":"A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2014-12","conditions":"Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II","enrollment":961},{"nctId":"NCT01805908","phase":"PHASE1","title":"Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)","status":"TERMINATED","sponsor":"Ontario Clinical Oncology Group (OCOG)","startDate":"2013-11","conditions":"Breast Cancer","enrollment":3},{"nctId":"NCT01121939","phase":"PHASE2","title":"Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2010-05","conditions":"Neuroendocrine Carcinoma","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Perjeta"],"phase":"phase_3","status":"active","brandName":"Pertuzumab Injection","genericName":"Pertuzumab Injection","companyName":"RemeGen Co., Ltd.","companyId":"remegen-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling. Used for HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy), HER2-positive early-stage breast cancer (neoadjuvant and adjuvant settings).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}